Pharmaceutical Quality Trends and Developments for 2025

This guide outlines key trends and developments impacting pharmaceutical quality in 2025. It addresses significant challenges such as drug shortages, which have persisted and are being closely monitored by regulators. The document discusses the FDA's new Quality Management Maturity (QMM) program, which aims to reward pharmaceutical companies that demonstrate advanced quality management practices. Additionally, the guide highlights innovations in manufacturing and clinical trial methods, including decentralized point-of-care manufacturing and decentralized clinical trials, which are gaining traction but face regulatory hurdles. The document also details recent regulatory updates and emphasizes the importance of adapting to evolving quality expectations. It stresses that the landscape for pharmaceutical quality will be increasingly complex in 2025, requiring companies to focus on consistency and quality of supply while navigating new legislative requirements. Overall, the guide serves as a critical resource for professionals in the pharmaceutical industry to prepare for the upcoming changes and challenges.